Skip to main content
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.

Schilling WHK. The Lancet Infectious Diseases 2025;:https://doi.org/10.1016/S1473-3099(25)00482-7.

Published on 5/11/2025

Post-COVID-19 condition in individuals infected with SARS-CoV-2 in autumn 2023 in the Netherlands: a prospective cohort study with pre- and post-infection data.

de Bruijn S. The Lancet Regional Health – Europe 2025;:https://doi.org/10.1016/j.lanepe.2025.101472.

Published on 5/11/2025

Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study.

Zhang B. The Lancet Infectious Diseases 2025;:https://doi.org/10.1016/S1473-3099(25)00476-1.

Published on 5/11/2025

Exploring the temporal relationship between stigma, disease manifestations, and health outcomes in post COVID-19 condition: a longitudinal descriptive study.

Damant RW. eClinicalMedicine 2025;:https://doi.org/10.1016/j.eclinm.2025.103531.

Published on 5/11/2025

Impact of COVID-19 pandemic on cognitive decline in community-dwelling older adults in Shanghai: a longitudinal study from 2010 to 2024.

Zhou X. The Lancet Regional Health – Western Pacific 2025;:https://doi.org/10.1016/j.lanwpc.2025.101697.

Published on 5/11/2025

SIREN study.

UK Health Security Agency (UKHSA); 2025.

Published on 14/10/2025

How vaping primes the lungs for COVID damage.

The Conversation; 2025.

Published on 13/10/2025


...
11
12
13
14
15